Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06600841
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-05
Brief Title:
Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in Recurrent Platinum-resistant Ovarian Cancer
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Adebrelimab Combined with Non-platinum Chemotherapy and Fuzuloparib in the Treatment of Patients with Recurrent Platinum-resistant Ovarian Cancer Sunrise Trial a Single-Arm Exploratory Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators explore the efficacy and safety of adebrelimab PD-L1 inhibitor plus Non-platinum chemotherapy and Fuzuloparib PARP inhibitor induction therapy followed by maintenance therapy with adebrelimab plus fluzoparib in platinum-resistant relapsedmetastatic ovarian cancer
Detailed Description:
Patients with platinum-resistant relapsedmetastatic ovarian cancer are treated with adebrelimab PD-L1 inhibitor plus Non-platinum chemotherapy and Fuzuloparib PARP inhibitor induction therapy for 6 cycles followed by maintenance therapy with adebrelimab plus fluzoparib
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None